Omeros Corp OMER:NASDAQ

Omeros (OMER) said late Wednesday it has submitted a briefing package to the US Food and Drug Administration after the agency raised concerns about narsoplimab in a complete response letter.

The company is seeking approval for narsoplimab as a potential treatment for a fatal disease called hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Omeros said it has also requested for a type A meeting with the FDA to resolve any outstanding items.

Price: 5.19, Change: +0.03, Percent Change: +0.58